bluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200 Day Moving Average of $1.23

Shares of bluebird bio, Inc. (NASDAQ:BLUE) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.23 and traded as low as $0.92. bluebird bio shares last traded at $0.98, with a volume of 8,509,356 shares traded.

Analyst Upgrades and Downgrades

BLUE has been the topic of a number of recent research reports. Wells Fargo & Company cut their target price on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Wednesday, March 27th. Royal Bank of Canada reissued a “sector perform” rating and issued a $6.00 target price on shares of bluebird bio in a report on Wednesday, March 27th. HSBC cut their target price on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating on the stock in a report on Tuesday, March 5th. Wedbush cut their price target on bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a report on Tuesday, March 19th. Finally, StockNews.com raised bluebird bio to a “sell” rating in a report on Thursday, March 28th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.46.

bluebird bio Trading Up 3.7 %

The stock’s 50 day moving average is $0.96 and its 200 day moving average is $1.22.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BLUE. Caxton Associates LP increased its stake in shares of bluebird bio by 187.9% during the third quarter. Caxton Associates LP now owns 152,389 shares of the biotechnology company’s stock valued at $463,000 after acquiring an additional 99,464 shares during the period. Wellington Management Group LLP grew its position in bluebird bio by 4.8% in the third quarter. Wellington Management Group LLP now owns 582,168 shares of the biotechnology company’s stock worth $1,770,000 after buying an additional 26,573 shares during the last quarter. Hudson Bay Capital Management LP grew its position in bluebird bio by 9.2% in the third quarter. Hudson Bay Capital Management LP now owns 327,500 shares of the biotechnology company’s stock worth $996,000 after buying an additional 27,500 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of bluebird bio by 0.8% in the third quarter. Vanguard Group Inc. now owns 5,617,460 shares of the biotechnology company’s stock valued at $17,077,000 after buying an additional 46,216 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new position in shares of bluebird bio in the fourth quarter valued at $37,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.